Roper Technologies, Inc. ROP

Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepting the CE mark. The test simultaneously screens for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD). This launch provides a crucial, ready-to-use solution for private and academic hospital labs, enabling the ea

Roche Holding (SWX:ROP) announced new R&D alliances focused on AI-powered therapeutics and metabolic disease programs in late September 2026. The group signed a research partnership with Earendil Labs to apply AI to bispecific antibody cancer therapies across multiple tumor types. Roche agreed a collaboration with Atavistik Bio to pursue allosteric small molecules for cardiovascular, renal and metabolic conditions. Enicepatide (CT-388) reported positive Phase 2 results in type 2 diabetes and...

A fat dividend yield can signal generosity or a countdown clock, and retirees who chase the wrong one lose twice when the payout finally breaks. Four tests separate the durable payers from the traps before the cut arrives.

Most dividend growth watchlists stop at consumer staples brands you already know, but three industrial compounders have quietly raised their payouts every year for over a quarter century while making things most investors never think about.

Roche Holding has delivered a powerful share price run over the last few years, which puts a bright spotlight on whether that market value still lines up with what the group earns. With a string of positive late stage trial results in oncology, neurology and renal disease, the question for you now is how much of that clinical momentum is already reflected in the price. Roche Holding has returned 59.8% over the past 3 years, so a lot of future expectations are already embedded in the current...

Roche Holding (SWX:ROP) is back in focus after partner Ionis reported that sefaxersen met the primary endpoint in the Phase 3 IMAgINATION trial for IgA nephropathy, delivering a statistically significant reduction in proteinuria compared with placebo. The latest clinical headlines come on top of a strong run for Roche Holding, with the share price up 8.32% over 90 days and 11.58% year to date. The 1-year total shareholder return of 44.02% points to momentum that has been building rather than...

Roche Holding (SWX:ROP) reported that its Phase III CELESTIMO trial of Lunsumio plus lenalidomide met its primary endpoint in relapsed or refractory follicular lymphoma. The CELESTIMO data support regulatory submissions to expand Lunsumio’s label to patients who have received at least one prior systemic therapy. Roche highlighted that the Lunsumio and lenalidomide combination is designed for outpatient administration, aiming to ease capacity pressure on hospitals. The CELESTIMO outcome for...

SCOTTSDALE, Ariz., September 15, 2026--Illumia, a leading provider of technology solutions that power payments, identity, commerce and foodservice operations across higher education, healthcare and corporate campuses, today announced the appointment of Don Smith to senior vice president & general manager, higher education. Smith will work across product, technology, commercial and customer teams to better connect Illumia’s products and experiences. The goal is to make it easier for colleges and

PORTLAND, Ore., Sept. 15, 2026 (GLOBE NEWSWIRE) -- National average truckload spot rates fell across all three equipment types in August, posting the steepest July-to-August declines in DAT’s 16-year rate history, according to DAT Freight & Analytics, provider of the industry’s leading load boards and freight analytics. The pullback also moved dry van and refrigerated (“reefer”) spot rates back below contract rates after spot rates exceeded contract rates in June and July. Spot rates post record

Procare Solutions, a leader in AI-enabled child care management software, trusted by more than 40,000 centers nationwide, announced today it has acquired Playground, a modern, all-in-one child care management platform recognized for its intuitive design, top-rated customer support and AI-powered tools, including Camber, the first AI assistant purpose-built for child care.

SARASOTA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the Piper Sandler Growth Frontiers Conference on Tuesday, September 15, 2026, at 8:30 AM (Central Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at www.ropertech.com. About Roper Technologies Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has a proven, long-term track r

Roper Technologies has notably underperformed the Dow over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Roche Holding (SWX:ROP) has been back in focus after Treeline Biosciences agreed to a clinical trial collaboration that combines TLN-121 with Roche bispecific antibodies glofitamab and mosunetuzumab for B-cell lymphomas. Roche Holding shares trade at CHF357.0, with a 90-day share price return of 10.63% and a year-to-date share price return of 9.68%. The 1-year total shareholder return of 34.18% points to momentum that has built alongside a steady stream of oncology and diagnostics...

Roche Holding stock has delivered a solid multi year gain, yet the valuation signals are more mixed, which leaves investors weighing a strong price record against a less clear cut verdict on how cheap the shares really are. After a 3 year climb, the stock now screens as neither an obvious bargain nor clearly expensive. Roche Holding has returned about 54.2% over the past 3 years, which puts extra focus on whether that share price performance already reflects most of the good news in the...

Roche Holding (SWX:ROP) announced a collaboration with Treeline Biosciences to study combination immunotherapies for B-cell lymphomas. The partners plan to evaluate advanced immune based treatments aimed at improving options for lymphoma patients. Roche received FDA clearance for its Elecsys pTau217 blood test as the first single biomarker assay to help both rule in and rule out amyloid pathology in Alzheimer’s disease. The Elecsys pTau217 test is intended to support clinicians in earlier...

SARASOTA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that it is presenting at the Citi Global TMT Conference on Thursday, September 10, 2026, at 8:50 AM (Eastern Time). A link to the webcast presentation will be available in the “Investors” section of the Company’s website at www.ropertech.com. About Roper Technologies Roper Technologies is a constituent of the Nasdaq 100, S&P 500, and Fortune 500. Roper has a proven, long-term track record of compo